Search:
You do not have permission to access this chart.
Please Sign Up or Login
News for Milestone Pharmaceuticals Inc. (MIST)
minutes ago | Banggood.com
58 minutes ago | Aliexpress.com
3 days ago | PRNewsWire
2 months ago | PRNewsWire
3 months ago | Benzinga
3 months ago | PRNewsWire
3 months ago | PRNewsWire
3 months ago | PRNewsWire
4 months ago | InvestorPlace
4 months ago | PRNewsWire
4 months ago | PRNewsWire
5 months ago | PRNewsWire
About:
Milestone Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes etripamil for the treatment of cardiovascular indications. It is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada, as well as for the treatment of atrial fibrillation, angina, and other cardiovascular indications. The company was founded in 2003 and is headquartered in Montréal, Canada.
Sector:
HealthcareIndustry:
BiotechnologyEmployees:
28Address:
Milestone Pharmaceuticals Inc. 1111 Dr. Frederik-Philips Boulevard Suite 420 Montreal QC H4M 2X6 CanadaWebsite:
Home